Shares of Jaguar Health JAGX moved higher by 1.5% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).
Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.
Guidance
Jaguar Health hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Aug 13, 2021
Time: 08:00 AM
ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039
Recent Stock Performance
Company's 52-week high was at $4.47
52-week low: $0.18
Price action over last quarter: Up 8.87%
Company Profile
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
